Arab Journal of Gastroenterology
Volume 11, Issue 2 , Pages 70-73 , June 2010

Faecal calprotectin in differentiating between functional and organic bowel diseases

  • Ahmed El-Badry

      Affiliations

    • Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
    • Corresponding Author InformationCorresponding author. Tel.: +20 237625642.
    • ,
  • Heba Sedrak

      Affiliations

    • Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
    • ,
  • Layla Rashed

      Affiliations

    • Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt

Received 25 February 2010 ,Accepted 11 April 2010.

References 

  1. Delvaux M. Functional bowel disorders and irritable bowel syndrome in Europe. Aliment Pharmacol Therap. 2003;18(Suppl. 3):75–79
  2. Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357(17):1731–1743
  3. Schröder O, Naumann M, Shastri Y, et al. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment Pharmacol Therap. 2007;26(7):1035–1042
  4. Costa F, Mumolo MJ, Marchi S, et al. Differential diagnosis between functional and organic intestinal disorders: is there a role for non-invasive tests?. World J Gastroenterol. 2007;13(2):219–223
  5. Cronin CC, Shanahan F. Immunological tests to monitor inflammatory bowel disease – have they delivered yet?. Am J Gastroenterol. 1998;93(3):295–297
  6. Suffredini AF, Fantuzzi G, Badolato R, et al. New insights into the biology of the acute phase response. J Clin Immunol. 1999;19(4):203–214
  7. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. New Engl J Med. 2004;351(26):2704–2714
  8. Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 1996;91(5):927–934
  9. Desai D, Faubion WA, Sandborn WJ. Biological activity markers in inflammatory bowel disease. Aliment Pharmacol Therap. 2007;25(3):247–255
  10. Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000;95(10):2831–2837
  11. Tibblea J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47:506–513
  12. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126(3):693–702
  13. Dale I, Brandtzaeg P, Fagerhol MK, et al. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol. 1985;84(1):24–34
  14. Andersson KB, Sletten K, Berntzen HB, et al. The leucocyte L1 protein: identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol. 1988;28(2):241–245
  15. Summerton CB, Longlands MG, Wiener K, et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14(8):841–845
  16. Hanai H, Takeuchi K, Iida T, et al. Relationship between fecal calprotectin, intestinal inflammation and peripheral blood neutrophils in patients with active ulcerative colitis. Digest Dis Sci. 2004;49(9):1438–1443
  17. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15–22
  18. Pardi DS, Sandborn WJ. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers?. Gut. 2005;54(3):321–322
  19. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34(1):50–54
  20. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27(9):793–798
  21. Fagerhol MK. Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein?. Clin Mol Pathol. 1996;49(2):M74–M79
  22. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997;50(3):113–123
  23. Ton H, Brandsnes Ø, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292(1–2):41–54
  24. El Nuamani NM, El Gendi HA, Zaki S, et al. Evaluation of the diagnostic yield of faecal calprotectin in Egyptian children with chronic diarrhea. Arab J Gastroenterol. 2007;8(4):132–135
  25. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491
  26. Mayer EA. Irritable bowel syndrome. New Engl J Med. 2008;358(16):1692–1699
  27. Spiegel BM, DeRosa VP, Gralnek IM, et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology. 2004;126(7):1721–1732
  28. Tomàs AB, Vidal MV, Camps AR. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig. 2007;99(12):689–693
  29. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP and IBD antibodies. Inflamm Bowel Dis. 2008;14(1):32–39

PII: S1687-1979(10)00052-3

doi: 10.1016/j.ajg.2010.04.009

Arab Journal of Gastroenterology
Volume 11, Issue 2 , Pages 70-73 , June 2010

Article Tools

* Image Usage & Resolution